Biosimilar Interchangeability: A Global Perspective
The Pink Sheet, United States
Biosimilars are the next big thing in cost-saving – that's been the promise for a while now, but why aren't we there yet? This session will discuss the successes and stumbles so far and gain insight on stimulating market access for interchangeable biosimilars.
Learning Objective : Describe the various approaches regulators and payors in different countries have used to encourage the uptake of biosimilars; Compare the success of various education efforts for biosimilars; Identify how to plan strategies to address and take advantage of the specific market conditions for biosimilars in different countries; Analyze the incentives offered to sponsors to develop interchangeable biosimilars.
Steinar Madsen, MD
Norwegian Medicines Agency, Norway
Molly Burich, MPH
Government Affairs - Biosimilars
Boehringer Ingelheim, United States
Chad Pettit, MBA
Executive Director, Value and Access, Biosimilars
Amgen Inc., United States